Nektar Therapeutics (NKTR)
$22.48
1.42 (5.94%)
NKTR Stock Quote Delayed 15 Minutes
Previous Close
$22.48
Market Cap
3.85B
PE Ratio
-28.10
EPS
-0.8
Volume (Avg. Vol.)
3.48M
Day's Range
22.28 - 23.87
52-Week Range
15.64 - 47.11
Dividend & Yield
N/A (N/A)
NKTR Stock Predictions, Articles, and Nektar Therapeutics News
3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics
Stock charts of VRTX, NKTR and SYMC are going to end the trading week knocking on the door of major moves.
3 Big Stock Charts for Friday: Nektar Therapeutics, Waters and A.O. Smith
As we move into the weekend, the stock charts of AOS, NKTR and WAT should be on your radar.
Nektar Therapeutics Stock Is a Buy After a Major Market Misread
Sellers dominated the trading action on Nektar stock after its preliminary clinical results. Over-reaction or justified selling? The market simply did not understand the results, hurting the NKTR stock price.
Why Bristol-Myers Squibb Company Shares Are Down Today
Bristol-Myers Squibb Company (BMY) shares were sliding as the company's collaboration cancer drug with Nektar Therapeutics (NKTR) did not impress investors.
Why Nektar Therapeutics Shares Are Plunging Today
Nektar Therapeutics (NKTR) took a heavy hit on Monday following the release of preliminary results from a recent clinical trial.
Nektar Therapeutics Stock Is Risky But Offers Big Reward
Nektar Therapeutics pulled back in recent weeks, and that is a good thing. Valuations are stretched, but the upside in NKTR stock is high if management delivers.
3 Stocks to Watch on Friday: Alphabet Inc (GOOG, GOOGL), Nektar Therapeutics (NKTR) and Solaredge Technologies Inc (SEDG)
Alphabet Inc (GOOG,GOOGL) is fixing latency issues with Google Home Max, while Nektar Therapeutics (NKTR) and Solaredge Technologies Inc (SEDG) reported earnings.
Stocks Weak Amid Fed Hawkishness on Rate Hikes
In the end, the Dow lost a fraction, the S&P gave back 0.2%, the Nasdaq gained a fraction and the Russell 2000 finished the day 0.5% lower.
Is Now the Time to Buy Into These 5 Biotech ETFs?
After a painful 2016, biotech stocks are recovering this year. What lies ahead? Let's look at 5 biotech ETFs to find out
16 Pharmaceuticals Stocks to Sell Now
The overall ratings of 16 Pharmaceuticals stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
13 Pharmaceuticals Stocks to Sell Now
The ratings of 13 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Biggest Movers in Manufacturing Stocks Now – BSPM RTTR SCL CCXI
The following stocks were the biggest movers and shakers in the Manufacturing sector today.
3 Pharmaceuticals Stocks to Buy Now
This week, 3 Pharmaceuticals stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
Navellier Ratings
Powered by Portfolio GraderTotal Grade
D
